Explore the latest in oncology R&D with Inpart’s new trends report, featuring emerging technologies, breakthrough innovations, and expert insights shaping the future of cancer research.
This week we talk with Immusoft CEO Sean Ainsworth to learn more about his journey in biotechnology and the work that Immusoft is doing in B-cell reprogramming
In this episode Labiotech talks with Lovisa Afzelius, a General Partner at Flagship and uncovers the ways in which Flagship is shaking up the biotech funding model